bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
2seventy bio Announces Upcoming Investor Events Read more about 2seventy bio Announces Upcoming Investor Events
bluebird bio Secures $75 Million in Private Placement Equity Financing Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing
bluebird bio at Morgan Stanley 19th Annual Healthcare Conference Read more about bluebird bio at Morgan Stanley 19th Annual Healthcare Conference
bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Read more about bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events
bluebird bio Reports Second Quarter Financial Results and Provides Operational Update Read more about bluebird bio Reports Second Quarter Financial Results and Provides Operational Update
2021 Wedbush PacGrow Healthcare Conference Read more about 2021 Wedbush PacGrow Healthcare Conference
bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events Read more about bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events
bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies Read more about Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies